Cargando…
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
Tumor-associated macrophages (TAMs), at the core of immunosuppressive cells and cytokines networks, play a crucial role in tumor immune evasion. Increasing evidences suggest that potential mechanisms of macrophage-mediated tumor immune escape imply interpretation and breakthrough to bottleneck of cu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501632/ https://www.ncbi.nlm.nih.gov/pubmed/34625124 http://dx.doi.org/10.1186/s40364-021-00327-3 |
_version_ | 1784580725519941632 |
---|---|
author | Qiu, Yingqi Chen, Tong Hu, Rong Zhu, Ruiyi Li, Chujun Ruan, Yingchen Xie, Xiaoling Li, Yuhua |
author_facet | Qiu, Yingqi Chen, Tong Hu, Rong Zhu, Ruiyi Li, Chujun Ruan, Yingchen Xie, Xiaoling Li, Yuhua |
author_sort | Qiu, Yingqi |
collection | PubMed |
description | Tumor-associated macrophages (TAMs), at the core of immunosuppressive cells and cytokines networks, play a crucial role in tumor immune evasion. Increasing evidences suggest that potential mechanisms of macrophage-mediated tumor immune escape imply interpretation and breakthrough to bottleneck of current tumor immunotherapy. Therefore, it is pivotal to understand the interactions between macrophages and other immune cells and factors for enhancing existing anti-cancer treatments. In this review, we focus on the specific signaling pathways through which TAMs involve in tumor antigen recognition disorders, recruitment and function of immunosuppressive cells, secretion of immunosuppressive cytokines, crosstalk with immune checkpoints and formation of immune privileged sites. Furthermore, we summarize correlative pre-clinical and clinical studies to provide new ideas for immunotherapy. From our perspective, macrophage-targeted therapy is expected to be the next frontier of cancer immunotherapy. |
format | Online Article Text |
id | pubmed-8501632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85016322021-10-20 Next frontier in tumor immunotherapy: macrophage-mediated immune evasion Qiu, Yingqi Chen, Tong Hu, Rong Zhu, Ruiyi Li, Chujun Ruan, Yingchen Xie, Xiaoling Li, Yuhua Biomark Res Review Tumor-associated macrophages (TAMs), at the core of immunosuppressive cells and cytokines networks, play a crucial role in tumor immune evasion. Increasing evidences suggest that potential mechanisms of macrophage-mediated tumor immune escape imply interpretation and breakthrough to bottleneck of current tumor immunotherapy. Therefore, it is pivotal to understand the interactions between macrophages and other immune cells and factors for enhancing existing anti-cancer treatments. In this review, we focus on the specific signaling pathways through which TAMs involve in tumor antigen recognition disorders, recruitment and function of immunosuppressive cells, secretion of immunosuppressive cytokines, crosstalk with immune checkpoints and formation of immune privileged sites. Furthermore, we summarize correlative pre-clinical and clinical studies to provide new ideas for immunotherapy. From our perspective, macrophage-targeted therapy is expected to be the next frontier of cancer immunotherapy. BioMed Central 2021-10-09 /pmc/articles/PMC8501632/ /pubmed/34625124 http://dx.doi.org/10.1186/s40364-021-00327-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Qiu, Yingqi Chen, Tong Hu, Rong Zhu, Ruiyi Li, Chujun Ruan, Yingchen Xie, Xiaoling Li, Yuhua Next frontier in tumor immunotherapy: macrophage-mediated immune evasion |
title | Next frontier in tumor immunotherapy: macrophage-mediated immune evasion |
title_full | Next frontier in tumor immunotherapy: macrophage-mediated immune evasion |
title_fullStr | Next frontier in tumor immunotherapy: macrophage-mediated immune evasion |
title_full_unstemmed | Next frontier in tumor immunotherapy: macrophage-mediated immune evasion |
title_short | Next frontier in tumor immunotherapy: macrophage-mediated immune evasion |
title_sort | next frontier in tumor immunotherapy: macrophage-mediated immune evasion |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501632/ https://www.ncbi.nlm.nih.gov/pubmed/34625124 http://dx.doi.org/10.1186/s40364-021-00327-3 |
work_keys_str_mv | AT qiuyingqi nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion AT chentong nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion AT hurong nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion AT zhuruiyi nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion AT lichujun nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion AT ruanyingchen nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion AT xiexiaoling nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion AT liyuhua nextfrontierintumorimmunotherapymacrophagemediatedimmuneevasion |